Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
Vaccitech plc
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments OXFORD, United Kingdom, August 10, 2023 -- Vaccitech plc , a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company’ s progress. “In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL,” said Bill Enright, Vaccitech’ s Chief Executive Officer. “Looking ahead, we rem..." |
|
| 07/26/2023 |
8-K
| Quarterly results |
| 06/01/2023 |
4
| Wright Robin (Director) has filed a Form 4 on Vaccitech plc|
Txns:
| Bought 13,750 shares
@ $2.6627, valued at
$36.6k
|
|
| 05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments OXFORD, United Kingdom, May 12, 2023 -- Vaccitech plc , a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company’ s progress. “2023 has kicked off strongly for Vaccitech. In the first quarter, we strengthened our leadership team with the addition of Dr. Nadège Pelletier as our new Chief Scientific Officer, we generated positive final proof of concept data from one of our hepatitis B trials, and very promising interim data from our human papillomavirus...",
"Investor Presentation dated May 2023" |
|
| 05/11/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 04/19/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/29/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/24/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/24/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/24/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 02/24/2023 |
4
| Pelletier Nadege (Chief Scientific Officer) has filed a Form 4 on Vaccitech plc|
Txns:
| Granted 485,000 options to buy
@ $2.9, valued at
$1.4M
|
|
| 02/24/2023 |
3
| Pelletier Nadege (Chief Scientific Officer) has filed a Form 3 on Vaccitech plc |
| 02/23/2023 |
4
| Griffiths Graham (Chief Business Officer) has filed a Form 4 on Vaccitech plc|
Txns:
| Granted 105,000 options to buy
@ $2.4, valued at
$252k
|
|
| 02/23/2023 |
4
| Enright William (CEO) has filed a Form 4 on Vaccitech plc|
Txns:
| Granted 440,000 options to buy
@ $2.4, valued at
$1.1M
|
|
| 02/23/2023 |
4
| Ellis Christopher (COO) has filed a Form 4 on Vaccitech plc|
Txns:
| Granted 105,000 options to buy
@ $2.4, valued at
$252k
|
|
| 02/23/2023 |
4
| Brown Gemma (CFO) has filed a Form 4 on Vaccitech plc|
Txns:
| Granted 33,100 options to buy
@ $2.4, valued at
$79.4k
|
|
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 02/10/2023 |
5
| Form 5 - Annual statement of changes in beneficial ownership of securities: |
| 01/20/2023 |
SC 13G/A
| M&G INVESTMENT MANAGEMENT LTD reports a 13.9% stake in Vaccitech Plc |
| 10/07/2022 |
SC 13G
| M&G INVESTMENT MANAGEMENT LTD reports a 14% stake in Vaccitech Plc |
| 10/04/2022 |
4
| M&G Alternatives Investment Management Ltd (10% Owner) has filed a Form 4 on Vaccitech plc|
Txns:
| Disposed of 4,108,752 shares
@ $0 |
|
| 10/04/2022 |
4
| M&G INVESTMENT MANAGEMENT LTD (10% Owner) has filed a Form 4 on Vaccitech plc|
Txns:
| Acquired 4,108,752 shares
@ $0 |
|
| 09/30/2022 |
8-K/A
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/28/2022 |
4
| Brown Gemma (CFO) has filed a Form 4 on Vaccitech plc|
Txns:
| Granted 334,000 options to buy
@ $3.07, valued at
$1M
|
|
|
|
|